Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination

Breast cancer (BC) prevention remains the ultimate cost-effective method to reduce the global burden of invasive breast cancer (IBC). To date, surgery and chemoprevention remain the main risk-reducing modalities for those with hereditary cancer syndromes, as well as high-risk non-hereditary breast l...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nadia Nocera Zachariah, Amrita Basu, Namrata Gautam, Ganesan Ramamoorthi, Krithika N. Kodumudi, Nagi B. Kumar, Loretta Loftus, Brian J. Czerniecki
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	breast cancer dendritic cell vaccine immunosurveillance DCIS ADH Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/ec880474820f49c39ed7097d18ed36b6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ec880474820f49c39ed7097d18ed36b6
record_format	dspace
spelling	oai:doaj.org-article:ec880474820f49c39ed7097d18ed36b62021-11-30T19:07:52ZIntercepting Premalignant, Preinvasive Breast Lesions Through Vaccination1664-322410.3389/fimmu.2021.786286https://doaj.org/article/ec880474820f49c39ed7097d18ed36b62021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.786286/fullhttps://doaj.org/toc/1664-3224Breast cancer (BC) prevention remains the ultimate cost-effective method to reduce the global burden of invasive breast cancer (IBC). To date, surgery and chemoprevention remain the main risk-reducing modalities for those with hereditary cancer syndromes, as well as high-risk non-hereditary breast lesions such as ADH, ALH, or LCIS. Ductal carcinoma in situ (DCIS) is a preinvasive malignant lesion of the breast that closely mirrors IBC and, if left untreated, develops into IBC in up to 50% of lesions. Certain high-risk patients with DCIS may have a 25% risk of developing recurrent DCIS or IBC, even after surgical resection. The development of breast cancer elicits a strong immune response, which brings to prominence the numerous advantages associated with immune-based cancer prevention over drug-based chemoprevention, supported by the success of dendritic cell vaccines targeting HER2-expressing BC. Vaccination against BC to prevent or interrupt the process of BC development remains elusive but is a viable option. Vaccination to intercept preinvasive or premalignant breast conditions may be possible by interrupting the expression pattern of various oncodrivers. Growth factors may also function as potential immune targets to prevent breast cancer progression. Furthermore, neoantigens also serve as effective targets for interception by virtue of strong immunogenicity. It is noteworthy that the immune response also needs to be strong enough to result in target lesion elimination to avoid immunoediting as it may occur in IBC arising from DCIS. Overall, if the issue of vaccine targets can be solved by interrupting premalignant lesions, there is a potential to prevent the development of IBC.Nadia Nocera ZachariahAmrita BasuNamrata GautamGanesan RamamoorthiKrithika N. KodumudiNagi B. KumarLoretta LoftusBrian J. CzernieckiFrontiers Media S.A.articlebreast cancerdendritic cellvaccineimmunosurveillanceDCISADHImmunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer dendritic cell vaccine immunosurveillance DCIS ADH Immunologic diseases. Allergy RC581-607
spellingShingle	breast cancer dendritic cell vaccine immunosurveillance DCIS ADH Immunologic diseases. Allergy RC581-607 Nadia Nocera Zachariah Amrita Basu Namrata Gautam Ganesan Ramamoorthi Krithika N. Kodumudi Nagi B. Kumar Loretta Loftus Brian J. Czerniecki Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination
description	Breast cancer (BC) prevention remains the ultimate cost-effective method to reduce the global burden of invasive breast cancer (IBC). To date, surgery and chemoprevention remain the main risk-reducing modalities for those with hereditary cancer syndromes, as well as high-risk non-hereditary breast lesions such as ADH, ALH, or LCIS. Ductal carcinoma in situ (DCIS) is a preinvasive malignant lesion of the breast that closely mirrors IBC and, if left untreated, develops into IBC in up to 50% of lesions. Certain high-risk patients with DCIS may have a 25% risk of developing recurrent DCIS or IBC, even after surgical resection. The development of breast cancer elicits a strong immune response, which brings to prominence the numerous advantages associated with immune-based cancer prevention over drug-based chemoprevention, supported by the success of dendritic cell vaccines targeting HER2-expressing BC. Vaccination against BC to prevent or interrupt the process of BC development remains elusive but is a viable option. Vaccination to intercept preinvasive or premalignant breast conditions may be possible by interrupting the expression pattern of various oncodrivers. Growth factors may also function as potential immune targets to prevent breast cancer progression. Furthermore, neoantigens also serve as effective targets for interception by virtue of strong immunogenicity. It is noteworthy that the immune response also needs to be strong enough to result in target lesion elimination to avoid immunoediting as it may occur in IBC arising from DCIS. Overall, if the issue of vaccine targets can be solved by interrupting premalignant lesions, there is a potential to prevent the development of IBC.
format	article
author	Nadia Nocera Zachariah Amrita Basu Namrata Gautam Ganesan Ramamoorthi Krithika N. Kodumudi Nagi B. Kumar Loretta Loftus Brian J. Czerniecki
author_facet	Nadia Nocera Zachariah Amrita Basu Namrata Gautam Ganesan Ramamoorthi Krithika N. Kodumudi Nagi B. Kumar Loretta Loftus Brian J. Czerniecki
author_sort	Nadia Nocera Zachariah
title	Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination
title_short	Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination
title_full	Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination
title_fullStr	Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination
title_full_unstemmed	Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination
title_sort	intercepting premalignant, preinvasive breast lesions through vaccination
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/ec880474820f49c39ed7097d18ed36b6
work_keys_str_mv	AT nadianocerazachariah interceptingpremalignantpreinvasivebreastlesionsthroughvaccination AT amritabasu interceptingpremalignantpreinvasivebreastlesionsthroughvaccination AT namratagautam interceptingpremalignantpreinvasivebreastlesionsthroughvaccination AT ganesanramamoorthi interceptingpremalignantpreinvasivebreastlesionsthroughvaccination AT krithikankodumudi interceptingpremalignantpreinvasivebreastlesionsthroughvaccination AT nagibkumar interceptingpremalignantpreinvasivebreastlesionsthroughvaccination AT lorettaloftus interceptingpremalignantpreinvasivebreastlesionsthroughvaccination AT brianjczerniecki interceptingpremalignantpreinvasivebreastlesionsthroughvaccination
_version_	1718406357828239360

Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination

Ejemplares similares